Globus Medical (NYSE:GMED – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 4.950-5.050 for the period, compared to the consensus EPS estimate of 4.740. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on GMED shares. Needham & Company LLC increased their price target on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Piper Sandler dropped their price objective on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research note on Monday, June 15th. Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. BMO Capital Markets initiated coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They set an “outperform” rating and a $94.00 target price for the company. Finally, Truist Financial lowered their target price on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Globus Medical has a consensus rating of “Moderate Buy” and an average price target of $102.08.
Check Out Our Latest Stock Analysis on Globus Medical
Globus Medical Price Performance
Globus Medical (NYSE:GMED – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million during the quarter, compared to analyst estimates of $782.88 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s revenue was up 5.9% compared to the same quarter last year. During the same period last year, the business earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities research analysts anticipate that Globus Medical will post 4.74 earnings per share for the current fiscal year.
Insider Activity at Globus Medical
In related news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares of the company’s stock, valued at $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is currently owned by insiders.
Globus Medical News Roundup
Here are the key news stories impacting Globus Medical this week:
- Positive Sentiment: Q2 earnings and revenue beat expectations. Globus Medical reported adjusted earnings of $1.34 per share, well above estimates ranging from $1.10 to $1.12 and up from $0.86 a year earlier. Revenue rose 5.9% year over year to $789.6 million, exceeding the $782.9 million consensus estimate. Globus Medical Q2 Earnings and Revenues Surpass Estimates
- Positive Sentiment: Full-year EPS guidance was raised above Wall Street expectations. The company forecast fiscal 2026 EPS of $4.95 to $5.05, compared with the analyst consensus of $4.74. Its revenue outlook of approximately $3.2 billion was broadly in line with expectations, suggesting the main upside is coming from profitability and earnings execution. Globus Medical Earnings Results
- Positive Sentiment: Profitability remained solid. Globus Medical reported an 18.92% net margin and 13.46% return on equity, reinforcing the favorable earnings reaction. Investors can review management’s outlook and operating commentary in the company’s earnings call transcript. Globus Medical Q2 2026 Earnings Call Transcript
- Neutral Sentiment: Analyst previews highlighted ongoing growth opportunities for Globus Medical but also cited tariffs, inflation and hospital spending as potential constraints on medtech demand. What to Expect From These 2 MedTech Stocks This Earnings Season?
- Neutral Sentiment: A Zacks valuation commentary identified GMED as a potentially attractive long-term value stock, but this is a broader investment view rather than a new company-specific catalyst. Why Globus Medical Is a Top Value Stock for the Long-Term
Institutional Trading of Globus Medical
Several institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC lifted its holdings in shares of Globus Medical by 45.9% during the first quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock valued at $1,622,000 after purchasing an additional 7,086 shares in the last quarter. Integrated Wealth Concepts LLC raised its position in Globus Medical by 33.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock worth $320,000 after buying an additional 1,085 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Globus Medical by 38.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock worth $2,228,000 after buying an additional 8,540 shares during the last quarter. Jones Financial Companies Lllp raised its position in Globus Medical by 237.3% in the 1st quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after buying an additional 598 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Globus Medical by 8.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock valued at $25,439,000 after acquiring an additional 28,027 shares during the period. 95.16% of the stock is currently owned by hedge funds and other institutional investors.
About Globus Medical
Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.
In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.
Read More
- Five stocks we like better than Globus Medical
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
